VERACYTE, Inc. (VCYT) intrinsic value & 10-year financials

VERACYTE, Inc. (VCYT) has a Graham intrinsic value of $27.24 per share. At $43.12 on Oct 17, 2026, the stock trades 58% above that value. Over the last 10 fiscal years revenue grew 25.9% a year to $517.1M, with an average return on invested capital of -38.0%.

Graham intrinsic value
$27.24
Share price (Oct 17, 2026)
$43.12
Price vs Graham value
58% above
Market cap
$3.5B
Revenue (FY2025)
$517.1M
Revenue growth (10-yr CAGR)
25.9%
ROIC (10-yr avg)
-38.0%
Free cash flow (FY2025)
$126.6M

VCYT 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $517.1M $66.4M $0.82 $126.6M 11.2% 5.7%
FY2024 $445.8M $24.1M $0.31 $63.8M 3.6% 1.7%
FY2023 $361.1M -$74.4M -$1.02 $34.3M -23.8% -9.4%
FY2022 $296.5M -$36.6M -$0.51 -$1.0M -13.9% -4.4%
FY2021 $219.5M -$75.6M -$1.11 -$37.0M -37.3% -14.8%
FY2020 $117.5M -$34.9M -$0.66 -$12.5M -30.1% -40.5%
FY2019 $120.4M -$12.6M -$0.27 -$6.0M -12.6% -25.3%
FY2018 $92.0M -$23.0M — -$15.4M -24.2% -80.4%
FY2017 $72.0M -$31.0M — -$25.7M -36.9% -99.1%
FY2016 $65.1M -$31.4M — -$32.2M -44.3% -113.9%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

VERACYTE, INC. is a consistent compounder, expanding top-line revenue at 25.9% annually over the past decade.

VERACYTE, INC. has historically struggled to out-earn its cost of capital, averaging just -38.1% ROIC.

VERACYTE, INC. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, VERACYTE, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $27.24 per share.

VCYT stock: frequently asked questions

What is the intrinsic value of VERACYTE, Inc. (VCYT) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 15.0% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, VCYT's intrinsic value is about $27.24 per share.

Is VCYT stock undervalued?

At $43.12 (close on Oct 17, 2026), VCYT trades 58% above its Graham value of $27.24. On Graham's terms the shares look fully priced. A formula is a starting point for research, not a recommendation.

How fast has VERACYTE, Inc. grown?

Revenue went from $65.1M in fiscal 2016 to $517.1M in fiscal 2025, a compound annual growth rate of 25.9%. Net income was $66.4M in fiscal 2025.

Does VERACYTE, Inc. generate free cash flow?

VERACYTE, Inc. generated $126.6M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 3 of the last 10 reported years.

What is VCYT's return on invested capital?

Average ROIC over the last 10 fiscal years was -38.0%, and average return on equity was -18.7%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this VCYT data come from?

From VERACYTE, Inc.'s annual 10-K filings on SEC EDGAR. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar medical laboratories stocks